Bristol Myers Squibb (NYSE: BMY) reported its third quarter 2024 earnings results today. Total revenues increased 8% year-over-year to $11.9 billion. Revenues
Bristol-Myers Squibb Co.
-(BMY)
XNYS:BMY
BMY Earnings: Bristol-Myers Squibb reports higher Q2 revenue and profit
Biotechnology company Bristol Myers Squibb (NYSE: BMY) Friday reported higher revenues and net profit for the second quarter of 2024. Net income
Key highlights from Bristol Myers Squibb’s (BMY) Q1 2024 earnings results
Bristol Myers Squibb (NYSE: BMY) reported first quarter 2024 earnings results today. Total revenues increased 5% year-over-year to $11.9 billion. When adjusted
Infographic: How Bristol Myers Squibb (BMY) performed in Q4 2023 financial results
Bristol Myers Squibb (NYSE: BMY) reported fourth quarter 2023 earnings results today. Total revenues inched up 1% to $11.5 billion versus the
BMY Earnings: Highlights of Bristol-Myers Squibb’s Q3 2023 results
Biotechnology company Bristol Myers Squibb (NYSE: BMY) Friday reported mixed results for the third quarter of 2023. The company also provided guidance
BMY Earnings: A snapshot of Bristol-Myers Squibb’s Q2 2023 results
Biotechnology company Bristol Myers Squibb (NYSE: BMY) on Thursday said its second-quarter adjusted earnings decreased year-over-year, hurt by a fall in revenues.
Bristol-Myers Squibb (BMY) reports higher Q1 profit; revenue down 3%
Biotechnology company Bristol Myers Squibb (NYSE: BMY) said its first-quarter adjusted earnings increased modestly, despite a decline in revenues. Net income attributable
BMY Earnings: Everything you need to know about Bristol Myers’ Q4 results
Bristol Myers Squibb (NYSE: BMY) on Thursday announced results for the fourth quarter of 2022, reporting lower earnings and revenues. The pharma
Bristol Myers Squibb (BMY) Earnings: 3Q22 Key Numbers
Bristol Myers Squibb (NYSE: BMY) reported revenues of $11.2 billion for the third quarter of 2022, down 3% from the same period
Bristol Myers Squibb (BMY) Q2 2022 Earnings: Key financials and quarterly highlights
Bristol Myers Squibb (NYSE: BMY) reported second quarter 2022 earnings results today. Total revenue grew 2% year-over-year to $11.9 billion. Net earnings
Bristol Myers Squibb (BMY) Q4 Earnings: Key financials and quarterly highlights
Bristol Myers Squibb (NYSE: BMY) reported fourth quarter 2021 earnings results today. Total revenues increased 8% year-over-year to $12 billion, driven by
Bristol-Myers bets on product pipeline to beat patent issues. Is BMY a buy?
The pharma sector has been on a stable growth trajectory lately, and the trend gathered momentum when the pandemic-related emergency made companies
BMY Earnings: Key quarterly highlights from Bristol-Myers Squibb Q3 financial results
Bristol-Myers Squibb Company (NYSE: BMY) reported second-quarter 2021 earnings. Revenues increased 10% year-over-year to $11.6 billion. Net earnings attributable to Bristol Myers
BMY Earnings: Key quarterly highlights from Bristol-Myers Squibb Q1 financial results
Bristol-Myers Squibb Company (NYSE: BMY) reported first quarter 2021 earnings results today. Revenues increased 3% year-over-year to $11.1 billion. Net earnings attributable
Earnings calendar for the week of April 26
Investor sentiment was hit by the government's proposal to levy higher capital gain tax on wealthy individuals, and the market shifted to
Strong pipeline, M&A synergies to keep Bristol Myers on growth path
Bristol Myers Squibb Company (NYSE: BMY) is thriving on its multi-pronged growth plan, based on strategic acquisitions and the promising pipeline. Recently,
Bristol Myers (BMY) stock gains after Q4 results beat Street view
Bristol-Myers Squibb Company (NYSE: BMY) Thursday reported stronger-than-expected fourth-quarter results. The company's stock gained in the pre-market session soon after the announcement.
Earnings calendar for the week of February 1
In a week that saw one of the worst stock selloffs, Gamestop came under spotlight after the stock experienced unprecedented fluctuations, marked
Bristol-Myers Squibb beats in Q3, raises guidance
Bristol-Myers Squibb Company (NYSE: BMY) reported third-quarter 2020 financial results before the market opened on Thursday. The pharmaceutical company reported a 75%
Bristol Myers looks to expand cardiovascular portfolio with MyoKardia acquisition
Bristol Myers Squibb (NYSE: BMY) agreed to acquire MyoKardia Inc. (NASDAQ: MYOK) for $13.1 billion in cash. The deal, which amounts to
Highlights of Bristol-Myers Squibb Company (NYSE: BMY) Q2 2020 Earnings
https://www.youtube.com/watch?v=dYv_jstT8BY&t=18s Pharmaceutical firm Bristol-Myers Squibb Company (NYSE: BMY) reported second-quarter 2020 financial results on Thursday morning. The results were better than analysts’